E2F8 and prostate adenocarcinoma: High E2F8 expression (HR = 3.03, p = 0.0002), particularly when co-elevated with AR (HR = 4.33, p = 0.0019), predicted poor survival in TCGA-PRAD, placing the long-used immunosuppressant as a repurposing candidate that disrupts the MELK/E2F8 axis [113].